Testing a new anti-inflammatory medication in rheumatoid arthritis patients

This is a Phase 1b trial testing SR-878, an experimental medication designed to reduce inflammation in rheumatoid arthritis by blocking a specific protein called iRhom2. The study is checking whether this medication is safe, what dose works best, and how your body processes it. Unlike some existing treatments that block only one inflammatory pathway, this medication targets multiple pathways, which researchers hope could provide better relief with fewer side effects.

In previous studies with healthy volunteers, this medication caused an unexpected temporary increase in inflammation markers, which led researchers to pause that study. However, animal studies suggested this reaction might not happen in people who already have an inflammatory condition like rheumatoid arthritis. This trial will test the medication directly in RA patients to confirm it is safe and effective in the population it's meant to treat.